173 related articles for article (PubMed ID: 29411659)
1. Safety and efficacy of miltefosine monotherapy and pentoxifylline associated with pentavalent antimony in treating mucosal leishmaniasis.
Ventin F; Cincurá C; Machado PRL
Expert Rev Anti Infect Ther; 2018 Mar; 16(3):219-225. PubMed ID: 29411659
[TBL] [Abstract][Full Text] [Related]
2. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis.
Machado PR; Lessa H; Lessa M; Guimarães LH; Bang H; Ho JL; Carvalho EM
Clin Infect Dis; 2007 Mar; 44(6):788-93. PubMed ID: 17304449
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Bolivian mucosal leishmaniasis with miltefosine.
Soto J; Toledo J; Valda L; Balderrama M; Rea I; Parra R; Ardiles J; Soto P; Gomez A; Molleda F; Fuentelsaz C; Anders G; Sindermann H; Engel J; Berman J
Clin Infect Dis; 2007 Feb; 44(3):350-6. PubMed ID: 17205440
[TBL] [Abstract][Full Text] [Related]
4. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.
Machado PR; Ampuero J; Guimarães LH; Villasboas L; Rocha AT; Schriefer A; Sousa RS; Talhari A; Penna G; Carvalho EM
PLoS Negl Trop Dis; 2010 Dec; 4(12):e912. PubMed ID: 21200420
[TBL] [Abstract][Full Text] [Related]
5. Oral Pentoxifylline Associated with Pentavalent Antimony: A Randomized Trial for Cutaneous Leishmaniasis.
Brito G; Dourado M; Guimarães LH; Meireles E; Schriefer A; de Carvalho EM; Machado PRL
Am J Trop Med Hyg; 2017 May; 96(5):1155-1159. PubMed ID: 28500815
[TBL] [Abstract][Full Text] [Related]
6. Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine.
Carregal VM; Lanza JS; Souza DM; Islam A; Demicheli C; Fujiwara RT; Rivas L; Frézard F
Parasitol Res; 2019 Oct; 118(10):3077-3084. PubMed ID: 31401656
[TBL] [Abstract][Full Text] [Related]
7. [The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis].
Sampaio RN; de Paula CD; Sampaio JH; Furtado Rde S; Leal PP; Rosa TT; Rodrigues ME; Veiga JP
Rev Soc Bras Med Trop; 1997; 30(6):457-63. PubMed ID: 9463192
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of miltefosine-pentoxifylline compared to miltefosine in the treatment of cutaneous leishmaniasis in C57Bl/6 mice.
Santarem AA; Greggianin GF; Debastiani RG; Ribeiro JB; Polli DA; Sampaio RN
Rev Soc Bras Med Trop; 2014 Jul; 47(4):517-20. PubMed ID: 25229296
[TBL] [Abstract][Full Text] [Related]
9. Mucosal leishmaniasis and miltefosine.
Tuon FF; Amato VS
Clin Infect Dis; 2007 Jun; 44(11):1525-6; author reply 1526-7. PubMed ID: 17479959
[No Abstract] [Full Text] [Related]
10. Miltefosine: oral treatment of leishmaniasis.
Soto J; Soto P
Expert Rev Anti Infect Ther; 2006 Apr; 4(2):177-85. PubMed ID: 16597200
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.
Chrusciak-Talhari A; Dietze R; Chrusciak Talhari C; da Silva RM; Gadelha Yamashita EP; de Oliveira Penna G; Lima Machado PR; Talhari S
Am J Trop Med Hyg; 2011 Feb; 84(2):255-60. PubMed ID: 21292895
[TBL] [Abstract][Full Text] [Related]
12. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
13. A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis.
Sampaio RNR; Silva JSFE; Paula CDR; Porto C; Motta JOCD; Pereira LIA; Martins SS; Barroso DH; Freire GSM; Gomes CM
Rev Soc Bras Med Trop; 2019 Mar; 52():e20180292. PubMed ID: 30942258
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony.
Lessa HA; Machado P; Lima F; Cruz AA; Bacellar O; Guerreiro J; Carvalho EM
Am J Trop Med Hyg; 2001 Aug; 65(2):87-9. PubMed ID: 11508396
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
Soto J; Rea J; Balderrama M; Toledo J; Soto P; Valda L; Berman JD
Am J Trop Med Hyg; 2008 Feb; 78(2):210-1. PubMed ID: 18256415
[TBL] [Abstract][Full Text] [Related]
16. In Situ Cellular Response Underlying Successful Treatment of Mucosal Leishmaniasis with a Combination of Pentavalent Antimonial and Pentoxifylline.
Faria DR; Barbieri LC; Koh CC; Machado PRL; Barreto CC; Lima CMF; Lessa MM; Carvalho E; Gollob KJ; Dutra WO
Am J Trop Med Hyg; 2019 Aug; 101(2):392-401. PubMed ID: 31219000
[TBL] [Abstract][Full Text] [Related]
17. The cure rate after different treatments for mucosal leishmaniasis in the Americas: A systematic review.
Carvalho JP; Silva SN; Freire ML; Alves LL; Souza CSA; Cota G
PLoS Negl Trop Dis; 2022 Nov; 16(11):e0010931. PubMed ID: 36395328
[TBL] [Abstract][Full Text] [Related]
18. Trial of oral miltefosine for visceral leishmaniasis.
Sundar S; Rosenkaimer F; Makharia MK; Goyal AK; Mandal AK; Voss A; Hilgard P; Murray HW
Lancet; 1998 Dec; 352(9143):1821-3. PubMed ID: 9851383
[TBL] [Abstract][Full Text] [Related]
19. A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis.
Martins SS; Barroso DH; Rodrigues BC; da Motta JOC; Freire GSM; Pereira LIA; Kurisky PS; Gomes CM; Sampaio RNR
Front Cell Infect Microbiol; 2021; 11():700323. PubMed ID: 34277476
[TBL] [Abstract][Full Text] [Related]
20. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
